register

News - Biotechnology

Agilex Biolabs acquires TetraQ for Asia Pacific expansion plans

Health Industry Hub | April 9, 2021 |

Biotech News: Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, today announced the acquisition of leading biolab TetraQ, based at the University of Queensland. Agilex Biolabs CEO Jason Valentine said they were very pleased with the purchase of the high-calibre bioanalytics company.

“TetraQ complements the Agilex Biolabs work in Australia and APAC with its expert staff and years of experience in regulated bioanalytical services,” he said. “The TetraQ purchase is part of our regional expansion plans. Agilex Biolabs is already the largest and most technologically advanced biolab in Australia, and the TetraQ addition to the business will further expand support for biotech clients running trials in Australia.”

“We are also looking forward to introducing our clients to the well-established TetraQ toxicology capabilities for their discovery and pre-clinical work in Australia, which can also attract the 43.5% tax rebate. The clinical trials bioanalytics sector is one of the fastest-growing services globally with Australia and APAC a preferred location for conducting trials – especially since the COVID-19 pandemic.”

TetraQ Director Dr Peter Tapley said he was very pleased that TetraQ was now an Agilex Biolabs company. “They are the leader in the sector with 24 years of experience, and offer our clients a significantly expanded range of services and technologies,” he said.

“Agilex Biolabs is known globally for its comprehensive services, specialist scientists, and the very latest technology. So this is the ideal next step for TetraQ and its staff and clients. I am pleased to be working alongside Agilex Biolabs’ CEO Jason Valentine as we expand our offering and leverage the synergies that make our two companies leaders in the sector.”

Agilex Biolabs specialises in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarker and immunological pharmacodynamics assessments utilising LC-MS/MS, immunoassay (Mesoscale, Gyrolab, Luminex) and flow cytometry (BD FACSymphony A3, 20 colour cell analyser).

Agilex also offers pharmacodynamics services that include immunobiology services using the latest state-of-the-art technology to support immunology, cell biology and mode of action assays.

Agilex Biolabs has 75 dedicated laboratory staff, and supports clinical research for biotech clients from US, Europe and APAC.


News - Pharmaceuticals

New funding to bring global CAR-T trials to young cancer patients

New funding to bring global CAR-T trials to young cancer patients

Health Industry Hub | September 14, 2026 |

The government is delivering the first investment under the $300 million MRFF Australian Cancer Research Program (ACRP), to bring international […]

More


News - Pharmaceuticals

Rising gynae cancers meets a system forcing patients to pay the price

Rising gynae cancers meets a system forcing patients to pay the price

Health Industry Hub | September 14, 2026 |

Sector leaders, government and women with lived experience unite in Canberra today to accelerate evidence-based action, as gynaecological cancer diagnoses […]

More


News - MedTech & Diagnostics

Analysis confirms private health insurance cuts targets vulnerable pensioners

Analysis confirms private health insurance cuts target vulnerable pensioners

Health Industry Hub | September 14, 2026 |

New analysis by the Parliamentary Budget Office (PBO) shows that half of the $3 billion dollars the Albanese Government expects […]

More


News - MedTech & Diagnostics

Chalmers retreats as startup tax backlash forces further changes

Chalmers retreats as startup tax backlash forces further changes

Health Industry Hub | September 14, 2026 |

The Albanese Government has been forced to retreat from several of the most contentious elements of its proposed startup tax […]

More


This content is copyright protected. Please subscribe to gain access.